Figure 3.

Forest plot of the hazard ratio for each NOAC vs warfarin among liver cirrhotic patients with NVAF taking oral anticoagulants. The NOAC group was associated with reduced risk of major GIB and all major bleeding compared with the warfarin group. Among NOACs, rivaroxaban was associated with lower risk of major GIB and all major bleeding than warfarin. Dabigatran was associated with lower risk of all major bleeding than warfarin. A indicates apixaban; D, dabigatran; GIB, gastrointestinal bleeding; HR, hazard ratio; ICH, intracranial hemorrhage; IS/SE, ischemic stroke/systemic embolism; NOAC, non–vitamin K antagonist oral anticoagulant; R, rivaroxaban; W, warfarin.